Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study
Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in N...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/14/1/101 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587775159828480 |
|---|---|
| author | Oludare ‘Sunbo Adewuyi Muhammad Shakir Balogun Hirono Otomaru Alash’le Abimiku Anthony Agbakizu Ahumibe Elsie Ilori Que Anh Luong Nwando Mba James Christopher Avong John Olaide Oyeladun Okunromade Adama Ahmad Afolabi Akinpelu Chinwe Lucia Ochu Babatunde Olajumoke Haruka Abe Chikwe Ihekweazu Adetifa Ifedayo Michiko Toizumi Hiroyuki Moriuchi Katsunori Yanagihara Jide Idris Lay-Myint Yoshida |
| author_facet | Oludare ‘Sunbo Adewuyi Muhammad Shakir Balogun Hirono Otomaru Alash’le Abimiku Anthony Agbakizu Ahumibe Elsie Ilori Que Anh Luong Nwando Mba James Christopher Avong John Olaide Oyeladun Okunromade Adama Ahmad Afolabi Akinpelu Chinwe Lucia Ochu Babatunde Olajumoke Haruka Abe Chikwe Ihekweazu Adetifa Ifedayo Michiko Toizumi Hiroyuki Moriuchi Katsunori Yanagihara Jide Idris Lay-Myint Yoshida |
| author_sort | Oludare ‘Sunbo Adewuyi |
| collection | DOAJ |
| description | Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria. We utilised 777 HBV-positive samples and epidemiological data from the two-stage sampled population-based, nationally representative Nigeria HIV/AIDS Indicator and Impact Survey conducted in 2018. We assessed 732 HBV DNA-extracted samples with detectable viral loads (VLs) for (sub-)genotypes and variants by whole-genome pre-amplification, nested PCR of the <i>s</i>-and <i>pol</i>-gene, and BigDye Terminator sequencing. We conducted HDV serology. In total, 19 out of the 36 + 1 states in Nigeria had a high prevalence of HBV (≥8%), with the highest prevalence (10.4%) in the north-central geopolitical zone. Up to 33.2% (95% CI 30.0–36.6) of the participants had detectable VLs of ≥300 copies/mL. The predominant circulating HBV genotype was E with 98.4% (95% CI 97.1–99.1), followed by A with 1.6% (95% CI 0.9–2.9). Drug-resistant associated variants and immune escape variants were detected in 9.3% and 0.4%, respectively. The seroprevalence of HDV was 7.34% (95% CI 5.5–9.2). Nigeria has subtype E as the major genotype with many variants. |
| format | Article |
| id | doaj-art-c0441b27bb994db68ba90ef4e53dda6b |
| institution | Kabale University |
| issn | 2076-0817 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj-art-c0441b27bb994db68ba90ef4e53dda6b2025-01-24T13:44:55ZengMDPI AGPathogens2076-08172025-01-0114110110.3390/pathogens14010101Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National StudyOludare ‘Sunbo Adewuyi0Muhammad Shakir Balogun1Hirono Otomaru2Alash’le Abimiku3Anthony Agbakizu Ahumibe4Elsie Ilori5Que Anh Luong6Nwando Mba7James Christopher Avong8John Olaide9Oyeladun Okunromade10Adama Ahmad11Afolabi Akinpelu12Chinwe Lucia Ochu13Babatunde Olajumoke14Haruka Abe15Chikwe Ihekweazu16Adetifa Ifedayo17Michiko Toizumi18Hiroyuki Moriuchi19Katsunori Yanagihara20Jide Idris21Lay-Myint Yoshida22Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, JapanNigeria Field Epidemiology and Laboratory Training Programme, Abuja 900231, NigeriaDepartment of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, JapanInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USAGraduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, JapanNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaDepartment of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, JapanNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaDepartment of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, JapanNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaVietnam Research Station, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, JapanNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaDepartment of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, JapanGraduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, JapanGraduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, JapanNigeria Centre for Disease Control and Prevention, Abuja 240102, NigeriaGraduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, JapanInformation on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria. We utilised 777 HBV-positive samples and epidemiological data from the two-stage sampled population-based, nationally representative Nigeria HIV/AIDS Indicator and Impact Survey conducted in 2018. We assessed 732 HBV DNA-extracted samples with detectable viral loads (VLs) for (sub-)genotypes and variants by whole-genome pre-amplification, nested PCR of the <i>s</i>-and <i>pol</i>-gene, and BigDye Terminator sequencing. We conducted HDV serology. In total, 19 out of the 36 + 1 states in Nigeria had a high prevalence of HBV (≥8%), with the highest prevalence (10.4%) in the north-central geopolitical zone. Up to 33.2% (95% CI 30.0–36.6) of the participants had detectable VLs of ≥300 copies/mL. The predominant circulating HBV genotype was E with 98.4% (95% CI 97.1–99.1), followed by A with 1.6% (95% CI 0.9–2.9). Drug-resistant associated variants and immune escape variants were detected in 9.3% and 0.4%, respectively. The seroprevalence of HDV was 7.34% (95% CI 5.5–9.2). Nigeria has subtype E as the major genotype with many variants.https://www.mdpi.com/2076-0817/14/1/101HBVgenotypesviral loadHDVdrug-resistant associated variantsNigeria |
| spellingShingle | Oludare ‘Sunbo Adewuyi Muhammad Shakir Balogun Hirono Otomaru Alash’le Abimiku Anthony Agbakizu Ahumibe Elsie Ilori Que Anh Luong Nwando Mba James Christopher Avong John Olaide Oyeladun Okunromade Adama Ahmad Afolabi Akinpelu Chinwe Lucia Ochu Babatunde Olajumoke Haruka Abe Chikwe Ihekweazu Adetifa Ifedayo Michiko Toizumi Hiroyuki Moriuchi Katsunori Yanagihara Jide Idris Lay-Myint Yoshida Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study Pathogens HBV genotypes viral load HDV drug-resistant associated variants Nigeria |
| title | Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study |
| title_full | Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study |
| title_fullStr | Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study |
| title_full_unstemmed | Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study |
| title_short | Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study |
| title_sort | molecular epidemiology drug resistant variants and therapeutic implications of hepatitis b virus and hepatitis d virus prevalence in nigeria a national study |
| topic | HBV genotypes viral load HDV drug-resistant associated variants Nigeria |
| url | https://www.mdpi.com/2076-0817/14/1/101 |
| work_keys_str_mv | AT oludaresunboadewuyi molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT muhammadshakirbalogun molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT hironootomaru molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT alashleabimiku molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT anthonyagbakizuahumibe molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT elsieilori molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT queanhluong molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT nwandomba molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT jameschristopheravong molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT johnolaide molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT oyeladunokunromade molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT adamaahmad molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT afolabiakinpelu molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT chinweluciaochu molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT babatundeolajumoke molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT harukaabe molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT chikweihekweazu molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT adetifaifedayo molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT michikotoizumi molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT hiroyukimoriuchi molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT katsunoriyanagihara molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT jideidris molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy AT laymyintyoshida molecularepidemiologydrugresistantvariantsandtherapeuticimplicationsofhepatitisbvirusandhepatitisdvirusprevalenceinnigeriaanationalstudy |